Symbols / ASND Stock $243.58 +2.50% Ascendis Pharma A/S

Healthcare • Biotechnology • Denmark • NMS
ASND (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Jan Moller Mikkelsen
Exch · Country NMS · Denmark
Market Cap 15.05B
Enterprise Value 15.45B
Income 495.93M
Sales 865.78M
FCF (ttm) 118.23M
Book/sh 9.24
Cash/sh 9.22
Employees 1,189
Insider 10d —
IPO Jan 28, 2015
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 26.68
Forward P/E 21.87
PEG —
P/S 17.38
P/B 26.35
P/C —
EV/EBITDA -1,511.44
EV/Sales 17.85
Quick Ratio 0.68
Current Ratio 1.00
Debt/Eq 183.75
LT Debt/Eq —
EPS (ttm) 9.13
EPS next Y 11.14
EPS Growth —
Revenue Growth 144.30%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-04-30
Earnings (prior) 2026-05-07
ROA -0.60%
ROE 3.33%
ROIC —
Gross Margin 89.04%
Oper. Margin 10.06%
Profit Margin 57.28%
Shs Outstand 61.78M
Shs Float 62.11M
Insider Own 0.82%
Instit Own 106.42%
Short Float 5.49%
Short Ratio 2.71
Short Interest 2.83M
52W High 250.74
vs 52W High -2.86%
52W Low 150.89
vs 52W Low 61.43%
Beta —
Impl. Vol. 56.16%
Rel Volume 0.61
Avg Volume 690.63K
Volume 423.72K
Target (mean) $297.28
Tgt Median $288.74
Tgt Low $254.89
Tgt High $343.50
# Analysts 7
Recom Strong_buy
Prev Close $237.65
Price $243.58
Change 2.50%
About

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$297.28
Mean price target
2. Current target
$243.58
Latest analyst target
3. DCF / Fair value
$34.45
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$243.58
Low
$254.89
High
$343.50
Mean
$297.28

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-11 main Barclays Overweight → Overweight $345
2026-05-08 main Wells Fargo Overweight → Overweight $326
2026-04-16 main B of A Securities Buy → Buy $292
2026-04-09 reit Wedbush Outperform → Outperform $273
2026-03-03 main RBC Capital Outperform → Outperform $275
2026-02-12 main Oppenheimer Outperform → Outperform $262
2026-02-12 main Wedbush Outperform → Outperform $273
2026-01-30 main B of A Securities Buy → Buy $260
2026-01-28 init Barclays — → Overweight $342
2026-01-20 main RBC Capital Outperform → Outperform $250
2026-01-20 main Wells Fargo Overweight → Overweight $330
2026-01-09 main Wells Fargo Overweight → Overweight $322
2026-01-07 reit TD Cowen Buy → Buy $325
2025-12-11 main Stifel Buy → Buy $256
2025-11-18 reit Wedbush Outperform → Outperform $220
2025-10-17 init Raymond James — → Strong Buy $271
2025-10-13 main Cantor Fitzgerald Overweight → Overweight $254
2025-10-09 main JP Morgan Overweight → Overweight $264
2025-09-02 main B of A Securities Buy → Buy $230
2025-08-19 main JP Morgan Overweight → Overweight $260
News
RSS: Latest ASND news
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
720.13
+98.03%
363.64
+36.34%
266.72
+421.20%
51.17
Operating Revenue
720.13
+98.03%
363.64
+36.34%
266.72
+421.20%
51.17
Cost Of Revenue
94.92
+114.46%
44.26
-0.31%
44.40
+265.78%
12.14
Reconciled Cost Of Revenue
87.04
+159.01%
33.61
-24.30%
44.40
+265.78%
12.14
Gross Profit
625.22
+95.76%
319.38
+43.66%
222.32
+469.52%
39.04
Operating Expense
761.49
+27.31%
598.15
-11.76%
677.86
+12.82%
600.85
Research And Development
303.62
-1.10%
307.00
-25.75%
413.45
+8.91%
379.62
Selling General And Administration
448.04
+57.72%
284.08
+7.44%
264.41
+22.50%
215.85
General And Administrative Expense
448.04
+57.72%
284.08
+9.77%
258.79
+19.89%
215.85
Salaries And Wages
210.42
+45.94%
144.18
+24.61%
115.71
+23.12%
93.98
Other Gand A
237.63
+69.86%
139.90
-2.22%
143.08
+17.41%
121.87
Total Expenses
856.40
+33.31%
642.40
-11.06%
722.26
+17.83%
612.99
Operating Income
-136.27
+51.12%
-278.76
+38.81%
-455.54
+18.92%
-561.81
Total Operating Income As Reported
-136.27
+51.12%
-278.76
+38.81%
-455.54
+18.92%
-561.81
EBITDA
-114.31
+60.59%
-290.02
+29.46%
-411.17
+22.30%
-529.18
Normalized EBITDA
-66.50
+73.97%
-255.50
+39.67%
-423.51
+23.57%
-554.13
Reconciled Depreciation
17.70
-0.10%
17.71
-6.33%
18.91
+5.31%
17.96
EBIT
-132.00
+57.10%
-307.74
+28.45%
-430.08
+21.39%
-547.13
Total Unusual Items
-47.81
-38.49%
-34.52
-379.63%
12.35
-50.52%
24.95
Total Unusual Items Excluding Goodwill
-47.81
-38.49%
-34.52
-379.63%
12.35
-50.52%
24.95
Net Income
-228.03
+39.69%
-378.08
+21.47%
-481.45
+17.45%
-583.19
Pretax Income
-212.65
+43.03%
-373.24
+21.28%
-474.14
+17.94%
-577.82
Net Non Operating Interest Income Expense
-44.88
-12.49%
-39.90
-217.79%
-12.55
+46.02%
-23.26
Interest Expense Non Operating
80.65
+23.12%
65.50
+48.65%
44.06
+43.62%
30.68
Net Interest Income
-44.88
-12.49%
-39.90
-217.79%
-12.55
+46.02%
-23.26
Interest Expense
80.65
+23.12%
65.50
+48.65%
44.06
+43.62%
30.68
Interest Income Non Operating
15.30
+6.55%
14.36
-14.81%
16.86
+127.00%
7.43
Interest Income
15.30
+6.55%
14.36
-14.81%
16.86
+127.00%
7.43
Other Income Expense
-31.50
+42.28%
-54.58
-802.35%
-6.05
-183.40%
7.25
Gain On Sale Of Security
-47.81
-38.49%
-34.52
-379.63%
12.35
-50.52%
24.95
Tax Provision
15.38
+217.63%
4.84
-33.68%
7.30
+35.82%
5.38
Tax Rate For Calcs
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
-10.04
-38.49%
-7.25
-379.63%
2.59
-50.52%
5.24
Net Income Including Noncontrolling Interests
-228.03
+39.69%
-378.08
+21.47%
-481.45
+17.45%
-583.19
Net Income From Continuing Operation Net Minority Interest
-228.03
+39.69%
-378.08
+21.47%
-481.45
+17.45%
-583.19
Net Income From Continuing And Discontinued Operation
-228.03
+39.69%
-378.08
+21.47%
-481.45
+17.45%
-583.19
Net Income Continuous Operations
-228.03
+39.69%
-378.08
+21.47%
-481.45
+17.45%
-583.19
Normalized Income
-190.26
+45.76%
-350.81
+28.58%
-491.20
+18.53%
-602.90
Net Income Common Stockholders
-228.03
+39.69%
-378.08
+21.47%
-481.45
+17.45%
-583.19
Diluted EPS
-3.76
+42.42%
-6.53
+23.63%
-8.55
+17.79%
-10.40
Basic EPS
-3.76
+42.42%
-6.53
+23.63%
-8.55
+17.79%
-10.40
Basic Average Shares
60.61
+4.69%
57.89
+0.00%
57.89
+3.25%
56.07
Diluted Average Shares
60.61
+4.69%
57.89
+0.00%
57.89
+3.25%
56.07
Diluted NI Availto Com Stockholders
-228.03
+39.69%
-378.08
+21.47%
-481.45
+17.45%
-583.19
Depreciation Amortization Depletion Income Statement
9.82
+39.10%
7.06
+25.59%
5.62
+4.58%
5.38
Depreciation And Amortization In Income Statement
9.82
+39.10%
7.06
+25.59%
5.62
+4.58%
5.38
Depreciation Income Statement
—
6.60
+17.32%
5.62
+4.58%
5.38
Earnings From Equity Interest
16.31
+181.30%
-20.06
-9.05%
-18.39
-3.94%
-17.70
Total Other Finance Cost
-20.47
-81.98%
-11.25
+23.24%
-14.65
-439.06%
4.32
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
1,302.57
+10.43%
1,179.49
+42.87%
825.59
-24.24%
1,089.74
Current Assets
1,108.98
+4.54%
1,060.86
+50.96%
702.72
-23.90%
923.47
Cash Cash Equivalents And Short Term Investments
616.04
+10.10%
559.54
+40.08%
399.44
-45.69%
735.46
Cash And Cash Equivalents
616.04
+10.10%
559.54
+42.68%
392.16
-11.83%
444.77
Other Short Term Investments
—
0.00
-100.00%
7.28
-97.50%
290.69
Receivables
157.70
-11.13%
177.44
+218.15%
55.77
+117.64%
25.63
Accounts Receivable
141.33
-15.00%
166.28
+363.51%
35.87
+201.21%
11.91
Other Receivables
14.58
+55.38%
9.38
-50.86%
19.10
+48.81%
12.83
Taxes Receivable
1.78
+0.34%
1.77
+121.32%
0.80
-9.17%
0.88
Inventory
301.53
+2.00%
295.61
+41.49%
208.93
+59.89%
130.67
Raw Materials
19.08
+8.45%
17.60
-5.22%
18.57
+93.07%
9.62
Work In Process
253.49
+7.55%
235.69
+37.81%
171.03
+51.51%
112.89
Finished Goods
28.96
-31.59%
42.33
+118.90%
19.34
+136.60%
8.17
Prepaid Assets
33.72
+19.26%
28.27
-26.72%
38.58
+21.63%
31.72
Total Non Current Assets
193.59
+63.18%
118.63
-3.44%
122.87
-26.10%
166.27
Net PPE
146.48
+48.39%
98.71
-10.77%
110.63
-14.30%
129.09
Gross PPE
222.90
+21.56%
183.36
+0.66%
182.15
+3.65%
175.74
Accumulated Depreciation
-76.42
+9.72%
-84.65
-18.36%
-71.52
-53.31%
-46.65
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
22.77
+3.79%
21.93
-20.06%
27.44
+9.99%
24.94
Other Properties
193.09
+36.82%
141.13
+4.28%
135.34
+3.57%
130.67
Leases
7.05
-65.28%
20.30
+4.76%
19.38
-3.75%
20.13
Goodwill And Other Intangible Assets
3.71
-7.89%
4.03
-8.85%
4.42
-8.47%
4.83
Goodwill
3.50
+0.00%
3.50
+0.00%
3.50
+0.00%
3.50
Other Intangible Assets
0.21
-59.66%
0.53
-42.32%
0.92
-30.68%
1.33
Investments And Advances
32.53
+139.60%
13.57
+138.74%
5.69
-81.31%
30.42
Long Term Equity Investment
32.53
+139.60%
13.57
+138.74%
5.69
-75.20%
22.93
Non Current Accounts Receivable
10.87
+369.14%
2.32
+8.93%
2.13
+10.78%
1.92
Total Liabilities Net Minority Interest
1,465.39
+14.02%
1,285.20
+32.32%
971.28
+17.53%
826.39
Current Liabilities
1,069.39
+17.79%
907.86
+23.27%
736.51
+2.75%
716.78
Payables And Accrued Expenses
97.08
-0.54%
97.62
+0.78%
96.86
-9.07%
106.52
Payables
97.08
-0.54%
97.62
+0.78%
96.86
-9.07%
106.52
Accounts Payable
90.66
-5.95%
96.39
+1.93%
94.57
-6.40%
101.03
Total Tax Payable
6.43
+425.94%
1.22
-46.85%
2.30
-58.12%
5.49
Income Tax Payable
6.43
+425.94%
1.22
-46.85%
2.30
-58.12%
5.49
Current Debt And Capital Lease Obligation
486.53
-1.02%
491.54
+16.68%
421.27
+2.01%
412.98
Current Debt
486.53
-1.02%
491.54
+16.68%
421.27
+2.01%
412.98
Other Current Borrowings
486.53
-1.02%
491.54
+16.68%
421.27
+2.01%
412.98
Current Capital Lease Obligation
—
—
14.17
+2.78%
13.79
Current Deferred Liabilities
4.94
+428.21%
0.94
-20.95%
1.18
0.00
Current Deferred Revenue
4.94
+428.21%
0.94
-20.95%
1.18
0.00
Other Current Liabilities
314.44
+43.82%
218.63
+18.51%
184.47
-2.88%
189.94
Total Non Current Liabilities Net Minority Interest
396.00
+4.95%
377.34
+60.72%
234.78
+114.19%
109.61
Long Term Debt And Capital Lease Obligation
385.25
+5.53%
365.08
+63.72%
223.00
+133.75%
95.40
Long Term Debt
385.25
+5.53%
365.08
+63.72%
223.00
+133.75%
95.40
Long Term Capital Lease Obligation
—
—
84.62
-11.30%
95.40
Non Current Deferred Liabilities
10.75
-12.33%
12.26
+4.07%
11.78
-17.13%
14.21
Non Current Deferred Revenue
1.12
-77.54%
5.00
-15.95%
5.95
-58.14%
14.21
Non Current Deferred Taxes Liabilities
9.62
+32.58%
7.26
+24.49%
5.83
0.00
Stockholders Equity
-162.82
-54.03%
-105.71
+27.45%
-145.70
-155.32%
263.35
Common Stock Equity
-162.82
-54.03%
-105.71
+27.45%
-145.70
-155.32%
263.35
Capital Stock
8.32
+2.12%
8.15
+5.16%
7.75
+0.96%
7.67
Common Stock
8.32
+2.12%
8.15
+5.16%
7.75
+0.96%
7.67
Share Issued
61.98
+2.12%
60.69
+5.17%
57.71
-0.96%
58.27
Ordinary Shares Number
61.38
+2.57%
59.84
+5.70%
56.61
-0.94%
57.15
Treasury Shares Number
0.60
-29.41%
0.85
-22.61%
1.09
-1.81%
1.11
Gains Losses Not Affecting Retained Earnings
—
—
-153.45
-160.02%
255.67
Total Equity Gross Minority Interest
-162.82
-54.03%
-105.71
+27.45%
-145.70
-155.32%
263.35
Total Capitalization
222.43
-14.24%
259.37
+235.55%
77.30
-78.45%
358.75
Working Capital
39.59
-74.12%
153.00
+552.82%
-33.79
-116.35%
206.69
Invested Capital
708.97
-5.59%
750.91
+50.61%
498.57
-35.40%
771.73
Total Debt
871.79
+1.77%
856.62
+32.96%
644.26
+26.73%
508.38
Net Debt
255.75
-13.91%
297.07
+17.84%
252.10
+296.32%
63.61
Capital Lease Obligations
—
—
98.79
-9.52%
109.19
Net Tangible Assets
-166.53
-51.76%
-109.73
+26.90%
-150.12
-158.07%
258.52
Tangible Book Value
-166.53
-51.76%
-109.73
+26.90%
-150.12
-158.07%
258.52
Available For Sale Securities
—
—
—
7.49
Current Provisions
166.40
+67.82%
99.15
+203.03%
32.72
+345.82%
7.34
Derivative Product Liabilities
—
—
143.30
-9.28%
157.95
Investmentin Financial Assets
—
0.00
0.00
-100.00%
7.49
Investmentsin Associatesat Cost
32.53
+139.60%
13.57
+138.74%
5.69
-75.20%
22.93
Other Equity Interest
-171.14
-50.32%
-113.86
+25.80%
-153.45
-160.02%
255.67
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
53.90
+117.60%
-306.20
+34.48%
-467.36
+5.72%
-495.70
Cash Flow From Continuing Operating Activities
53.90
+117.60%
-306.20
+34.48%
-467.36
+5.72%
-495.70
Net Income From Continuing Operations
-228.03
+39.69%
-378.08
+21.47%
-481.45
+17.45%
-583.19
Depreciation Amortization Depletion
17.70
-0.10%
17.71
-6.33%
18.91
+5.31%
17.96
Depreciation
17.21
-0.24%
17.25
-6.41%
18.43
+5.22%
17.51
Amortization Cash Flow
0.49
+4.93%
0.47
-3.31%
0.48
+8.78%
0.44
Depreciation And Amortization
17.70
-0.10%
17.71
-6.33%
18.91
+5.31%
17.96
Amortization Of Intangibles
0.49
+4.93%
0.47
-3.31%
0.48
+8.78%
0.44
Other Non Cash Items
87.06
+83.86%
47.35
+2306.38%
-2.15
+49.40%
-4.24
Stock Based Compensation
116.17
+21.63%
95.51
+43.28%
66.66
+3.86%
64.18
Provisionand Write Offof Assets
—
—
—
6.14
Asset Impairment Charge
5.28
0.00
-100.00%
7.83
0.00
Deferred Tax
15.38
+217.63%
4.84
-33.68%
7.30
+35.82%
5.38
Deferred Income Tax
15.38
+217.63%
4.84
-33.68%
7.30
+35.82%
5.38
Operating Gains Losses
-16.31
-181.67%
19.97
+8.53%
18.40
+3.84%
17.72
Gain Loss On Sale Of PPE
0.00
+100.00%
-0.09
-1920.00%
0.01
-77.27%
0.02
Change In Working Capital
70.96
+166.22%
-107.16
-7.39%
-99.79
-700.08%
-12.47
Change In Receivables
15.59
+113.14%
-118.61
-261.90%
-32.77
-184.22%
-11.53
Change In Inventory
-5.92
+93.17%
-86.68
-10.76%
-78.26
-41.60%
-55.27
Change In Prepaid Assets
-6.05
-158.23%
10.39
+191.05%
-11.41
-78.08%
-6.41
Change In Payables And Accrued Expense
-10.37
-138.47%
26.96
+659.36%
3.55
-92.27%
45.94
Change In Other Working Capital
77.72
+27.88%
60.77
+218.06%
19.11
+29.16%
14.79
Investing Cash Flow
-8.48
-223.40%
6.88
-97.60%
286.47
+364.06%
61.73
Cash Flow From Continuing Investing Activities
-8.48
-223.40%
6.88
-97.60%
286.47
+364.06%
61.73
Net PPE Purchase And Sale
-8.48
-1678.83%
-0.48
+80.05%
-2.39
+51.74%
-4.95
Purchase Of PPE
-8.48
-494.60%
-1.43
+41.56%
-2.44
+83.15%
-14.49
Sale Of PPE
0.00
-100.00%
0.95
+1762.75%
0.05
-99.47%
9.54
Capital Expenditure
-8.48
-494.60%
-1.43
+41.56%
-2.44
+83.15%
-14.49
Capital Expenditure Reported
—
—
—
—
Net Investment Purchase And Sale
0.00
-100.00%
7.35
-97.45%
288.87
+333.17%
66.69
Purchase Of Investment
—
0.00
0.00
+100.00%
-213.84
Sale Of Investment
0.00
-100.00%
7.35
-97.45%
288.87
+2.97%
280.53
Net Business Purchase And Sale
—
—
0.00
0.00
Purchase Of Business
—
—
0.00
0.00
Net Intangibles Purchase And Sale
—
—
0.00
0.00
Purchase Of Intangibles
—
—
0.00
0.00
Financing Cash Flow
36.33
-91.82%
443.93
+230.57%
134.29
-66.15%
396.77
Cash Flow From Continuing Financing Activities
36.33
-91.82%
443.93
+230.57%
134.29
-66.15%
396.77
Net Issuance Payments Of Debt
-21.96
-117.88%
122.79
-2.40%
125.82
-74.68%
496.93
Issuance Of Debt
0.00
-100.00%
134.16
-1.54%
136.26
-72.93%
503.28
Repayment Of Debt
-21.96
-93.21%
-11.37
-8.88%
-10.44
-64.22%
-6.36
Long Term Debt Issuance
0.00
-100.00%
134.16
-1.54%
136.26
-72.93%
503.28
Long Term Debt Payments
-21.96
-93.21%
-11.37
-8.88%
-10.44
-64.22%
-6.36
Net Long Term Debt Issuance
-21.96
-117.88%
122.79
-2.40%
125.82
-74.68%
496.93
Net Common Stock Issuance
-17.40
-105.61%
309.91
0.00
+100.00%
-105.31
Common Stock Payments
-17.40
0.00
0.00
+100.00%
-105.31
Repurchase Of Capital Stock
-17.40
0.00
0.00
+100.00%
-105.31
Proceeds From Stock Option Exercised
87.08
+185.37%
30.51
+196.66%
10.29
+99.61%
5.15
Net Other Financing Charges
-11.40
+40.93%
-19.29
-964.62%
-1.81
—
Changes In Cash
81.74
-43.47%
144.61
+410.35%
-46.59
-25.28%
-37.19
Effect Of Exchange Rate Changes
-25.24
-210.85%
22.77
+479.01%
-6.01
-116.83%
35.69
Beginning Cash Position
559.54
+42.68%
392.16
-11.83%
444.77
-0.34%
446.27
End Cash Position
616.04
+10.10%
559.54
+42.68%
392.16
-11.83%
444.77
Free Cash Flow
45.41
+114.76%
-307.62
+34.52%
-469.80
+7.92%
-510.19
Common Stock Issuance
0.00
-100.00%
309.91
0.00
0.00
Earnings Losses From Equity Investments
-16.31
-181.30%
20.06
+9.05%
18.39
+3.94%
17.70
Interest Paid CFO
-22.93
-50.84%
-15.21
+2.98%
-15.67
-68.62%
-9.29
Interest Received CFO
15.30
+6.46%
14.37
-15.69%
17.05
+106.12%
8.27
Issuance Of Capital Stock
0.00
-100.00%
309.91
0.00
0.00
Taxes Refund Paid
-6.68
-21.17%
-5.51
-23.42%
-4.47
-148766.67%
-0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category